Abstract：Gliomas is a global cell-originated tumor that is the most common primary intracranial tumor. World Health Organization (WHO) classification of glioma isWHO Ⅰ-Ⅳ,and WHO Ⅰ-Ⅱ are the lower-grade gliomas(LGG),WHO Ⅲ-Ⅳ are the higher-grade gliomas(HGG).With the development of modern radiotherapy and radiobiology,radiation therapy become an integral role in treating gliomas.Different grade of the gliomas will have different characteristics and treatment strategy. China expert diagnosis and treatment guildline of central nervous system glioma has been published in 2016. However, there was no relevant consensus specialized on glioma radiotherapy in China untill now.Therefore,after discussion and communication according to evidence-based medicine,a consensus was made among China Society for Radiation Oncology (CSTRO) composed of Chinese glioma experts.The consensus includes radiation therapy for HGG,LGG,diffuse intrinsic pontine glioma, ependymom, recurrent spinal cord glioblastoma,elderly patients,pediatric gliomas and pseudoprogression.The consensus will provide in-depth analysis and summarize the concernedquestion of radiation therapy in clinical work.Meanwhile,this consensus would strive to further standardize the application of radiation therapy in glioma treatment to provide evidence-based guidance.
[1] Muir CS,Storm HH Polednak A.Brain and other nervous system tumours[J].Cancer Sur,1994(19-20):369-392. [2] de Robles P,Fiest KM,Frolkis AD,et al. The worldwide incidence and prevalence of primary brain tumors:A systematic review and meta-analysis[J].Neuro-Oncol,2015,17(6):776-783.DOI:10.1093/neuonc/nou283. [3] Louis DN,Perry A,Reifenberger G,et al. The 2016 world health organization classification of tumors of the central nervous system:A summary[J].Acta Neuropathol,2016,131(6):803-820.DOI:10.1007/s00401-016-1545-1. [4] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中华医学杂志,2016,96(7):485-509.DOI:10.3760/cma.j.issn.0376-2491.2013.31.002. The China central nervous system,glioma diagnosis and treatment guidelines\"editorial committee. Chinese glioma diagnosis and treatment of central nervous system guide (2015).[J].Chin J Med,2016,96(7):485-509.DOI:10.3760/cma.j.issn.0376-2491.2013.31.002. [5] Cabrera AR,Kirkpatrick JP,Fiveash JB,et al. Radiation therapy for glioblastoma:Executive summary of an american society for radiation oncology evidence-based clinical practice guideline[J].Pract Radiat Oncol,2016,6(4):217-225.DOI:10.1016/j.prro.2016.03.007. [6] Valduvieco I,Verger E,Bruna J,et al. Impact of radiotherapy delay on survival in glioblastoma[J].Clin Transl Oncol,2013,15(4):278-282.DOI:10.1007/s12094-012-0916-x. [7] Graus F,Bruna J,Pardo J,et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in spain[J].Neuro-Oncol,2013,15(6):797-805.DOI:10.1093/neuonc/not013. [8] Sun MZ,Oh T,Ivan ME,et al. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma[J].J Neurosurg,2015,122(5):1144-1150.DOI:10.3171/2014.9.JNS14193. [9] leehen NM Stenning SP.A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The medical research council brain tumour working party[J].Br J Cancer,1991,64(4):769-774. [10] Selker RG,Shapiro WR,Burger P,et al. The brain tumor cooperative group nih trial 87-01:A randomized comparison of surgery,external radiotherapy,and carmustine versus surgery,interstitial radiotherapy boost,external radiation therapy,and carmustine[J].Neurosurgery,2002,51(2):343-355,discussion 355-347. [11] Nelson DF,Diener-West M,Horton J,et al. Combined modality approach to treatment of malignant gliomas—re-evaluation of rtog 7401/ecog 1374 with long-term follow-up:A joint study of the radiation therapy oncology group and the eastern cooperative oncology group[J].NCI Monographs,1988(6):279-284. [12] Chang CH,Horton J,Schoenfeld D,et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study[J].Cancer,1983,52(6):997-1007. [13] Monjazeb AM,Ayala D,Jensen C,et al. A phase i dose escalation study of hypofractionated imrt field-in-field boost for newly diagnosed glioblastoma multiforme[J].Int J Radiat Oncol Biol Phys,2012,82(2):743-748.DOI:10.1016/j.ijrobp.2010.10.018. [14] Souhami L,Seiferheld W,Brachman D,et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme:Report of radiation therapy oncology group 93-05 protocol[J].Int J Radiat Oncol Biol Phys,2004,60(3):853-860.DOI:10.1016/j.ijrobp.2004.04.011. [15] Laperriere NJ,Leung PM,McKenzie S,et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma[J].Int J Radiat Oncol Biol Phys,1998,41(5):1005-1011. [16] Chan JL,Lee SW,Fraass BA,et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy[J].J Clin Oncol,2002,20(6):1635-1642.DOI:10.1200/jco.2002.20.6.1635. [17] Lawrence YR,Li XA,el Naqa I,et al. Radiation dose-volume effects in the brain[J].Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):S20-27.DOI:10.1016/j.ijrobp.2009.02.091. [18] Stupp R,Mason WP,van den Bent MJ,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J].New Engl J Med,2005,352(10):987-996.DOI:10.1056/NEJMoa043330. [19] Chang EL,Akyurek S,Avalos T,et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma[J].Int J Radiat Oncol Biol Phys,2007,68(1):144-150.DOI:10.1016/j.ijrobp.2006.12.009. [20] Gilbert MR,Wang M,Aldape KD,et al. Dose-dense temozolomide for newly diagnosed glioblastoma:A randomized phase iii clinical trial[J].J Clin Oncol,2013,31(32):4085-4091.DOI:10.1200/jco.2013.49.6968. [21] Stupp R,Hegi ME,Gorlia T,et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated mgmt promoter (centric eortc 26071-22072 study):a multicentre,randomised,open-label,phase 3 trial[J].Lancet Oncol,2014,15(10):1100-1108.DOI:10.1016/s1470-2045(14)70379-1. [22] Minniti G,Amelio D,Amichetti M,et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide[J].Radiother Oncol,2010,97(3):377-381.DOI:10.1016/j.radonc.2010.08.020. [23] Kuhnt D,Becker A,Ganslandt O,et al. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative mri guidance[J].Neuro-Oncol,2011,13(12):1339-1348.DOI:10.1093/neuonc/nor133. [24] Lacroix M,Abi-Said D,Fourney DR,et al. A multivariate analysis of 416 patients with glioblastoma multiforme:Prognosis,extent of resection,and survival[J].J Neurosurg,2001,95(2):190-198.DOI:10.3171/jns.2001.95.2.0190. [25] Niyazi M,Brada M,Chalmers AJ,et al. Estro-acrop guideline"target delineation of glioblastomas"[J].Radiother Oncol,2016,118(1):35-42.DOI:10.1016/j.radonc.2015.12.003. [26] Stupp R,Hegi ME,Mason WP,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study:5-year analysis of the eortc-ncic trial[J]. Lancet Oncol,2009,10(5):459-466.DOI:10.1016/s1470-2045(09)70025-7. [27] Hau P,Koch D,Hundsberger T,et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma[J].Neurology,2007,68(9):688-690.DOI:10.1212/01.wnl.0000255937.27012.ee. [28] Roldan-Urgoiti GB,Singh AD,Easaw JC.Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme[J].J Neuro-Oncol,2012,108(1):173-177.DOI:10.1007/s11060-012-0826-3. [29] Gilbert MR,Dignam JJ,Armstrong TS,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma[J].New Engl J Med,2014,370(8):699-708.DOI:10.1056/NEJMoa1308573. [30] Shaw E,Scott C,Souhami L,et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases:final report of rtog protocol 90-05[J].Int J Radiat Oncol Biol Phys,2000,47(2):291-298. [31] Pinzi V,Orsi C,Marchetti M,et al. Radiosurgery reirradiation for high-grade glioma recurrence:a retrospective analysis[J].Neurol Sci,2015,36(8):1431-1440.DOI:10.1007/s10072-015-2172-7. [32] Combs SE,Thilmann C,Edler L,et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas:long-term results in 172 patients treated in a single institution[J].J Clin Oncol,2005,23(34):8863-8869.DOI:10.1200/jco.2005.03.4157. [33] Chamberlain MC.Temozolomide for recurrent low-grade spinal cord gliomas in adults[J].Cancer,2008,113(5):1019-1024.DOI:10.1002/cncr.23677. [34] Chamberlain MC,Johnston SK.Recurrent spinal cord glioblastoma:Salvage therapy with bevacizumab[J].J Neuro-Oncol,2011,102(3):427-432.DOI:10.1007/s11060-010-0330-6. [35] Forsyth PA,Petrov E,Mahallati H,et al. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas[J].J Clin Oncol,1997,15(5):2076-2081.DOI:10.1200/jco.1997.15.5.2076. [36] Fouke SJ,Benzinger T,Gibson D,et al. The role of imaging in the management of adults with diffuse low grade glioma:A systematic review and evidence-based clinical practice guideline[J].J Neuro-Oncol,2015,125(3):457-479.DOI:10.1007/s11060-015-1908-9. [37] Buckner JC,Shaw EG,Pugh SL,et al. Radiation plus procarbazine,ccnu,and vincristine in low-grade glioma[J].New Engl J Med,2016,374(14):1344-1355.DOI:10.1056/NEJMoa1500925. [38] van den Bent MJ,Wefel JS,Schiff D,et al. Response assessment in neuro-oncology (a report of the rano group):assessment of outcome in trials of diffuse low-grade gliomas[J].Lancet Oncol,2011,12(6):583-593.DOI:10.1016/s1470-2045(11)70057-2. [39] Pignatti F,van den Bent M,Curran D,et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma[J].J Clin Oncol,2002,20(8):2076-2084.DOI:10.1200/jco.2002.08.121. [40] Baumert BG,Hegi ME,van den Bent MJ,et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (eortc 22033-26033):a randomised,open-label,phase 3 intergroup study[J].Lancet Oncol,2016,17(11):1521-1532.DOI:10.1016/s1470-2045(16)30313-8. [41] Vogelbaum MA,Hu C,Peereboom DM,et al. Phase Ⅱ trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas:Long term results of rtog br0131[J].J Neuro-Oncol,2015,124(3):413-420.DOI:10.1007/s11060-015-1845-7. [42] Shaw EG,Berkey B,Coons SW,et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma:Results of a prospective clinical trial[J].J Neurosurg,2008,109(5):835-841.DOI:10.3171/jns/2008/109/11/0835. [43] Brat DJ,Verhaak RG,Aldape KD,et al. Comprehensive,integrative genomic analysis of diffuse lower-grade gliomas[J].New Engl J Med,2015,372(26):2481-2498.DOI:10.1056/NEJMoa1402121. [44] Fisher BJ,Hu C,Macdonald DR,et al. Phase Ⅱ study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas:Preliminary results of radiation therapy oncology group 0424[J].Int J Radiat Oncol Biol Phys,2015,91(3):497-504.DOI:10.1016/j.ijrobp.2014.11.012. [45] Shaw E,Arusell R,Scheithauer B,et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma:Initial report of a north central cancer treatment group/radiation therapy oncology group/eastern cooperative oncology group study[J].J Clin Oncol,2002,20(9):2267-2276.DOI:10.1200/jco.2002.09.126. [46] Karim AB,Maat B,Hatlevoll R,et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma:European organization for research and treatment of cancer (EORTC) study 22844[J].Int J Radiat Oncol Biol Phys,1996,36(3):549-556. [47] Shaw EG,Wang M,Coons SW,et al. Randomized trial of radiation therapy plus procarbazine,lomustine,and vincristine chemotherapy for supratentorial adult low-grade glioma:initial results of rtog 9802[J].J Clin Oncol,2012,30(25):3065-3070.DOI:10.1200/jco.2011.35.8598. [48] Janssens GO,Jansen MH,Lauwers SJ,et al. Hypofractionation vs. conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma:a matched-cohort analysis[J].Int J Radiat Oncol Biol Phys,2013,85(2):315-320.DOI:10.1016/j.ijrobp.2012.04.006. [49] Bailey S,Howman A,Wheatley K,et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy—results of a united kingdom phase ii trial (cns 2007 04)[J].Eur J Cancer (Oxford,England:1990),2013,49(18):3856-3862.DOI:10.1016/j.ejca.2013.08.006. [50] Cohen KJ,Heideman RL,Zhou T,et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas:A report from the children′s oncology group[J].Neuro-Oncol,2011,13(4):410-416.DOI:10.1093/neuonc/noq205. [51] Sirachainan N,Pakakasama S,Visudithbhan A,et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma[J].Neuro-Oncol,2008,10(4):577-582.DOI:10.1215/15228517-2008-025. [52] Haas-Kogan DA,Banerjee A,Poussaint TY,et al. Phase ii trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas[J].Neuro-Oncol,2011,13(3):298-306.DOI:10.1093/neuonc/noq202. [53] Asaid M,Preece PD,Rosenthal MA,et al. Ependymoma in adults:Local experience with an uncommon tumour[J].J Clin Neuroscience,2015,22(9):1392-1396.DOI:10.1016/j.jocn.2015.03.020. [54] Aizer AA,Ancukiewicz M,Nguyen PL,et al. Natural history and role of radiation in patients with supratentorial and infratentorial who grade ii ependymomas:Results from a population-based study[J].J Neuro-Oncol,2013,115(3):411-419.DOI:10.1007/s11060-013-1237-9. [55] Acquaye AA,Vera E,Gilbert MR,et al. Clinical presentation and outcomes for adult ependymoma patients[J].Cancer,2017,123(3):494-501.DOI:10.1002/cncr.30355. [56] Lin Y,Jea A,Melkonian SC,et al. Treatment of pediatric grade ii spinal ependymomas:A population-based study[J].J Neurosurg Pediat,2015,15(3):243-249.DOI:10.3171/2014.9.peds1473. [57] Cage TA,Clark AJ,Aranda D,et al. A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas[J].J Neurosurg Pediat,2013,11(6):673-681.DOI:10.3171/2013.2.peds12345. [58] Massimino M,Miceli R,Giangaspero F,et al. Final results of the second prospective aieop protocol for pediatric intracranial ependymoma[J].Neuro-Oncol,2016,18(10):1451-1460.DOI:10.1093/neuonc/now108. [59] Reni M,Brandes AA,Vavassori V,et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors[J].Cancer,2004,100(6):1221-1229.DOI:10.1002/cncr.20074. [60] Tensaouti F,Ducassou A,Chaltiel L,et al. Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma[J].Radiother Oncol,2017,122(3):362-367.DOI:10.1016/j.radonc.2016.12.025. [61] Swanson EL,Amdur RJ,Morris CG,et al. Intracranial ependymomas treated with radiotherapy:Long-term results from a single institution[J].J Neuro-Oncol,2011,102(3):451-457.DOI:10.1007/s11060-010-0344-0. [62] Lobon MJ,Bautista F,Riet F,et al. Re-irradiation of recurrent pediatric ependymoma:Modalities and outcomes:a twenty-year survey[J].Springer Plus,2016,5(1):879.DOI:10.1186/s40064-016-2562-1. [63] Gramatzki D,Roth P,Felsberg J,et al. Chemotherapy for intracranial ependymoma in adults[J].BMC Cancer,2016,16:287.DOI:10.1186/s12885-016-2323-0. [64] Ruda R,Bosa C,Magistrello M,et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult:a retrospective study[J].Neuro-Oncol,2016,18(2):261-268.DOI:10.1093/neuonc/nov167. [65] Brandes AA,Franceschi E,Tosoni A,et al. Mgmt promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients[J].J Clin Oncol,2008,26(13):2192-2197.DOI:10.1200/jco.2007.14.8163. [66] Li H,Li J,Cheng G,et al. Idh mutation and mgmt promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy[J].Clin Neurol Neurosurg,2016,151:31-36.DOI:10.1016/j.clineuro.2016.10.004. [67] Li S,Yan C,Huang L,et al. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship:a single institutional review of 77 patients from china[J].Neuro-Oncol,2012,14(1):109-116.DOI:10.1093/neuonc/nor185. [68] Galldiks N,Kocher M Langen KJ.Pseudoprogression after glioma therapy:an update[J].Exp Rev Neurothera,2017,17(11):1109-1115.DOI:10.1080/14737175.2017.1375405. [69] Ostrom QT,Gittleman H,Fulop J,et al. Cbtrus statistical report:Primary brain and central nervous system tumors diagnosed in the united states in 2008-2012[J].Neuro-Oncol,2015,17 Suppl 4:iv1-iv62.DOI:10.1093/neuonc/nov189. [70] Malmstrom A,Gronberg BH,Marosi C,et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma:The nordic randomised,phase 3 trial[J].Lancet Oncol,2012,13(9):916-926.DOI:10.1016/s1470-2045(12)70265-6. [71] Wick W,Platten M,Meisner C,et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly:The noa-08 randomised,phase 3 trial[J].Lancet Oncol,2012,13(7):707-715.DOI:10.1016/s1470-2045(12)70164-x. [72] Roa W,Kepka L,Kumar N,et al. International atomic energy agency randomized phase iii study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme[J].J Clin Oncol,2015,33(35):4145-4150.DOI:10.1200/jco.2015.62.6606. [73] van den Bent MJ,Afra D,de Witte O,et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults:the eortc 22845 randomised trial[J].Lancet (London,England),2005,366(9490):985-990.DOI:10.1016/s0140-6736(05)67070-5. [74] Kaloshi G,Benouaich-Amiel A,Diakite F,et al. Temozolomide for low-grade gliomas:Predictive impact of 1p/19q loss on response and outcome[J].Neurology,2007,68(21):1831-1836.DOI:10.1212/01.wnl.0000262034.26310.a2. [75] Kesari S,Schiff D,Drappatz J,et al. Phase Ⅱ study of protracted daily temozolomide for low-grade gliomas in adults[J].Clin Cancer Res,2009,15(1):330-337.DOI:10.1158/1078-0432.ccr-08-0888. [76] Ostrom QT,Gittleman H,Liao P,et al. Cbtrus statistical report:Primary brain and central nervous system tumors diagnosed in the united states in 2007-2011[J].Neuro-Oncol,2014,16 Suppl 4:iv1-63.DOI:10.1093/neuonc/nou223. [77] Pollack IF,Hamilton RL,Sobol RW,et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas:results from the ccg-945 cohort[J].J Clin Oncol,2006,24(21):3431-3437.DOI:10.1200/jco.2006.05.7265. [78] Ho CY,Mobley BC,Gordish-Dressman H,et al. A clinicopathologic study of diencephalic pediatric low-grade gliomas with braf v600 mutation[J].Acta Neuropathol,2015,130(4):575-585.DOI:10.1007/s00401-015-1467-3. [79] Schwartzentruber J,Korshunov A,Liu XY,et al. Driver mutations in histone h3.3 and chromatin remodelling genes in paediatric glioblastoma[J].Nature,2012,482(7384):226-231.DOI:10.1038/nature10833. [80] Shaw EG Wisoff JH.Prospective clinical trials of intracranial low-grade glioma in adults and children[J].Neuro-Oncol,2003,5(3):153-160.DOI:10.1215/s1152851702000601. [81] Sievert AJ Fisher MJ.Pediatric low-grade gliomas[J].J Child Neurol,2009,24(11):1397-1408.DOI:10.1177/0883073809342005. [82] Gururangan S,Fisher MJ,Allen JC,et al. Temozolomide in children with progressive low-grade glioma[J].Neuro-Oncol,2007,9(2):161-168.DOI:10.1215/15228517-2006-030. [83] Chintagumpala M,Eckel SP,Krailo M,et al. A pilot study using carboplatin,vincristine,and temozolomide in children with progressive/symptomatic low-grade glioma:a children′s oncology group studydagger[J].Neuro-Oncol,2015,17(8):1132-1138.DOI:10.1093/neuonc/nov057. [84] Greenberger BA,Pulsifer MB,Ebb DH,et al. Clinical outcomes and late endocrine,neurocognitive,and visual profiles of proton radiation for pediatric low-grade gliomas[J].Int J Radiat Oncol Biol Phys,2014,89(5):1060-1068.DOI:10.1016/j.ijrobp.2014.04.053. [85] Williams NL,Rotondo RL,Bradley JA,et al. Late effects after radiotherapy for childhood low-grade glioma[J].Am J Clin Oncol,2016.DOI:10.1097/coc.0000000000000267. [86] Haeberli S,Grotzer MA,Niggli FK,et al. A psychoeducational intervention reduces the need for anesthesia during radiotherapy for young childhood cancer patients[J].Radiat Oncol (London,England),2008,3:17.DOI:10.1186/1748-717x-3-17. [87] Klosky JL,Tyc VL,Srivastava DK,et al. Brief report:Evaluation of an interactive intervention designed to reduce pediatric distress during radiation therapy procedures[J].J Pediat Psychol,2004,29(8):621-626.DOI:10.1093/jpepsy/jsh064.
2018, Vol. 27 
